Optimizing Evidence-Based Care in Generalized Myasthenia Gravis: Advances in FcRn Antagonist Therapy and Personalized Treatment Strategies
Date: September 14, 2025
Time: 7:30 pm to 8:30 pm
Room: Grand Ballrooms 5 - 6 (Third Floor Level)
Track: Satellite Symposia
Session Description
The live symposium, led by two nationally recognized gMG experts and a clinical moderator, will provide an in-depth examination of generalized myasthenia gravis (gMG), focusing on the latest advancements in neonatal Fc receptor (FcRn) antagonist therapy. Experts will explore the mechanistic role of FcRn antagonism in gMG, its impact on albumin homeostasis, and current clinical safety and efficacy data, emphasizing their implications for practice, including patient selection and individualized care.
Furthermore, expert faculty will address strategies for monitoring patients on FcRn antagonist therapy to ensure optimal long-term efficacy and safety outcomes. At key points during the symposium, the faculty will introduce interactive, case-based polling questions with multiple-choice answers designed to assess learnersā current knowledge, competence, and attitudes, while actively engaging them in applying the latest evidence.
Faculty
Facilitator: Michael R. Stinchon, Jr., RPh
Speaker: James F. Howard, Jr., MD
Speaker: Ali Habib, MD
Provided By: Prime Education, LLC, an ANA2025 Platinum Level Sponsor!
Learning Objectives
- Explain the mechanism of action of FcRn antagonists and how it targets the underlying pathophysiology of gMG.
- Evaluate the latest clinical safety and efficacy data supporting the use of FcRn antagonists in gMG treatment.
- Identify appropriate candidates for FcRn antagonist therapy by evaluating key clinical indicators and patient-specific factors.
- Develop personalized FcRn antagonist treatment plans, considering dosing, delivery method, and patient goals.
- Apply effective monitoring strategies for FcRn antagonist therapy, accounting for its effects on albumin recycling and patient safety.
RSVP TODAY!
Financial Support
This program is supported through an independent educational grant from Argenx.
This session is not sponsored or programmed by the American Neurological Association (ANA). The faculty are presenting on behalf of, and are paid consultants for, Prime Education, LLC.
Continuing Education Credits:
- 1.0 CME/CE forĀ PhysiciansĀ (ACCME)
- 1.0 CME/CE forĀ Physician AssistantsĀ (AAPA)
- 1.0 CH/CE forĀ Nurse PractitionersĀ (AANP)
- 1.0 CPE forĀ PharmacistsĀ (ACPE + NABP)
- 1.0 CNE forĀ NursesĀ (ANCC)
See more here.
Disclaimer
The ANA values the participation of our corporate partners and is supportive of the role that members of this community continue to play in our efforts to provide neurologists & neuroscientists with quality educational programs. These symposia are not part of the ANA official educational program, and the sessions and content are not endorsed by ANA.
The ANA does not provide continuing medical education (CME) credits for Satellite Symposia and assumes no responsibility for credits offered by other organizations. Accredited providers are solely responsible for the content, quality, and scientific integrity of their Satellite Symposia.